BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37428201)

  • 1. Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).
    Pohlmann A; Bentgens E; Schülke C; Kuron D; Reicherts C; Marx J; Angenendt L; Mikesch JH; Lenz G; Stelljes M; Schliemann C
    Ann Hematol; 2023 Sep; 102(9):2543-2553. PubMed ID: 37428201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Shimomura Y; Hara M; Katoh D; Hashimoto H; Ishikawa T
    Ann Hematol; 2018 Jun; 97(6):1049-1056. PubMed ID: 29455235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HLA-10/10 matched unrelated donor versus sibling donor hematopoietic stem cell transplantation for adult acute myeloid leukemia].
    Yao JF; Zhang GX; Shen YY; Zhang RL; He Y; Wei JL; Jiang EL; Yang DL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):460-466. PubMed ID: 31340617
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
    Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
    [No Abstract]   [Full Text] [Related]  

  • 6. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
    Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
    Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of umbilical cord blood transplantation and hematopoietic stem cell transplantation from HLA-matched sibling donors in the treatment of myelodysplastic syndrome-EB or acute myeloid leukemia with myelodysplasia-related changes].
    Zhu J; Tang BL; Song KD; Zhang XH; Zhu XY; Yao W; Wan X; Liu HL; Sun ZM
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):294-300. PubMed ID: 31104440
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive Factors and Outcomes after Allogeneic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia in Brazil.
    Silva WF; Cysne DN; Kerbauy MN; Colturato I; Maia ACA; Tucunduva L; Barros GMN; Colturato VAR; Hamerschlak N; Rocha V
    Transplant Cell Ther; 2022 Nov; 28(11):763.e1-763.e7. PubMed ID: 35914726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea.
    Ji YS; Ahn JS; Yun J; Jang GH; Lim SH; Kim SH; Kim CK; Won JH; Park SK
    Yonsei Med J; 2023 Feb; 64(2):123-132. PubMed ID: 36719020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 12. Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).
    Pochon C; Detrait M; Dalle JH; Michel G; Dhédin N; Chalandon Y; Brissot E; Forcade E; Sirvent A; Izzadifar-Legrand F; Michallet M; Renard C; Yakoub-Agha I; Gonzales F; Bay JO; Kanold J; Cornillon J; Bulabois CE; Angoso M; Nguyen S; Balza M; Chevallier P; Rialland F; Bazarbachi A; Beguin Y; Huynh A; Ménard AL; Schneider P; Neven B; Paillard C; Raus N; Albuisson E; Remen T; Rubio MT
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2083-2097. PubMed ID: 34480598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
    Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
    Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
    Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
    J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of long-term mortality after total body irradiation-based and melphalan-based chemotherapy conditioning for acute myeloid leukemia.
    Gruber I; Koelbl O; Treutwein M; Zeman F; Herr W; Holler E; Edinger M; Wolff D
    Ann Hematol; 2023 Aug; 102(8):2199-2211. PubMed ID: 37347269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
    Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
    Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
    Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
    Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total Marrow Irradiation for Second Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia.
    Dominietto A; Vagge S; di Grazia C; Bregante S; Raiola AM; Varaldo R; Gualandi F; Gusinu M; Barra S; Agostinelli S; Angelucci E; Hui S
    Transplant Cell Ther; 2023 Aug; 29(8):506.e1-506.e6. PubMed ID: 37094701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
    Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.